C4 Therapeutics (CCCC) Stock Price, News & Analysis

C4 Therapeutics, Inc. (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company focused on targeted protein degradation to create a new generation of medicines. According to company disclosures, C4 Therapeutics (C4T) is dedicated to advancing targeted protein degradation science and is progressing targeted oncology programs through clinical studies while using its TORPEDO® platform to design and optimize small-molecule medicines for difficult-to-treat diseases. The company states that its degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, with the potential to address drug resistance, historically undruggable targets and improve patient outcomes.

Core focus and therapeutic approach

C4 Therapeutics operates in the biological product manufacturing space within the broader manufacturing sector, with a focus on human therapeutics. Its work centers on targeted protein degradation, including heterobivalent degraders (such as BiDAC™) and molecular glue or MonoDAC® degraders, as described in its public communications. By designing orally bioavailable degraders that can selectively remove disease-driving proteins, the company aims to impact oncology and non-oncology indications where there is a strong degrader rationale and significant unmet medical need.

Key clinical program: Cemsidomide

The company’s lead program is cemsidomide, an investigational, orally bioavailable small-molecule IKZF1/3 degrader. C4 Therapeutics describes cemsidomide as a potent and selective degrader of IKZF1 and IKZF3, transcription factors that drive multiple myeloma and certain lymphomas. Clinical data from a Phase 1 trial in relapsed/refractory multiple myeloma show that cemsidomide in combination with dexamethasone has demonstrated anti-myeloma activity, immunomodulatory effects, and a differentiated safety and tolerability profile in a heavily pretreated patient population.

The company has completed enrollment and dose escalation in its Phase 1 multiple myeloma trial and has reported overall response rates at higher dose levels, along with durable responses and limited dose reductions. C4 Therapeutics has outlined plans for a registrational Phase 2 MOMENTUM trial of cemsidomide plus dexamethasone in later-line relapsed/refractory multiple myeloma and a Phase 1b trial evaluating cemsidomide and dexamethasone in combination with a BCMA-targeted bispecific antibody such as elranatamab. Company communications describe a development strategy that could support potential accelerated approval pathways in distinct lines of therapy, subject to regulatory review and clinical outcomes.

Cemsidomide beyond multiple myeloma

Beyond multiple myeloma, C4 Therapeutics has evaluated cemsidomide in non-Hodgkin’s lymphoma, including peripheral T-cell lymphoma, in a Phase 1 trial. The company reports that cemsidomide monotherapy in lymphoma has shown a well-tolerated profile and evidence of anti-lymphoma activity across dose levels, with responses observed in peripheral T-cell lymphoma patients. C4 Therapeutics has also indicated plans to open expansion cohorts in specific lymphoma subtypes as part of its ongoing clinical work.

Additional pipeline programs

In addition to cemsidomide, C4 Therapeutics highlights other degrader programs:

• CFT8919: An orally bioavailable allosteric degrader designed to be potent and selective against EGFR bearing an oncogenic L858R mutation. Preclinical data described by the company indicate activity in in vitro and in vivo models of L858R-driven non-small cell lung cancer, including models with additional EGFR mutations that confer resistance to approved EGFR inhibitors. C4 Therapeutics has a strategic partnership with Betta Pharmaceuticals to develop CFT8919 in Greater China, where a Phase 1 clinical trial is underway, while C4T retains rights in the United States, European Union and other regions.
• CFT1946: An orally bioavailable, brain-penetrant small-molecule degrader of BRAF V600 mutations in solid tumors. C4 Therapeutics advanced CFT1946 into a Phase 1/2 global clinical trial in patients refractory to BRAF inhibitors and has reported pharmacodynamic and safety data supporting proof of mechanism and the therapeutic potential of degrading mutant BRAF V600. The company has stated that it does not plan to advance the BRAF program beyond the current Phase 1 trial on its own and is seeking partnership opportunities.
• BIIB142 (collaboration with Biogen): A degrader of IRAK4 that originated from C4 Therapeutics’ collaboration with Biogen. The company has announced that Biogen’s investigational new drug application for BIIB142 has been accepted by the U.S. Food and Drug Administration, with Biogen responsible for clinical development and commercialization. C4 Therapeutics is eligible for milestone payments under this collaboration.

Discovery strategy and non-oncology expansion

C4 Therapeutics has described an internal discovery strategy that builds on its experience in targeted protein degradation to pursue novel targets in clinically validated pathways. The company reports that it is focusing discovery efforts on inflammation, neuro-inflammation and neuro-degenerative diseases, with a goal of developing degrader medicines for several novel targets that modulate validated inflammatory pathways. C4 Therapeutics indicates that its expertise includes designing highly catalytic, orally bioavailable degraders that can penetrate the blood-brain barrier and achieve high central nervous system exposures in preclinical models.

The company has also extended its capabilities to identify molecular glue degraders using DNA-encoded library (DEL) technology, including for targets with and without specific structural motifs such as G- and RT-loops, as described in its public updates. This work supports both its internal pipeline and partnered discovery efforts.

Collaborations and partnerships

C4 Therapeutics has entered into multiple research and development collaborations with larger biopharmaceutical companies. Public disclosures reference collaborations with Biogen, Roche and Merck KGaA, Darmstadt, Germany, among others. These collaborations involve applying C4T’s targeted protein degradation expertise and TORPEDO platform to discover and optimize degraders across a range of target classes and therapeutic areas, including oncology and non-oncology indications.

The company has reported achieving preclinical and clinical milestones under these collaborations, including milestone payments from Biogen related to BIIB142 and from partners such as Roche and Merck KGaA for progress on degrader programs, including projects within the KRAS family. C4 Therapeutics also notes that it may earn additional research milestones and potential licensing fees from these partnerships as programs advance.

Capital markets and corporate structure

C4 Therapeutics’ common stock trades on The Nasdaq Global Select Market under the ticker symbol CCCC, as reflected in its SEC filings. The company has used both at-the-market equity programs and underwritten offerings to raise capital, as described in its public filings and press releases. In an underwritten offering entered into through an underwriting agreement with Jefferies LLC, TD Securities (USA) LLC and Evercore Group L.L.C., C4 Therapeutics sold shares of common stock, pre-funded warrants and accompanying Class A and Class B warrants, and disclosed that net proceeds were expected to extend its cash runway to the end of 2028, excluding any additional proceeds from warrant exercises.

In a separate SEC filing, the company reported that stockholders approved an amendment to its certificate of incorporation to increase the number of authorized shares of common stock, reflecting its need for financial flexibility to support ongoing research, clinical development and corporate activities. C4 Therapeutics has also reported regular quarterly financial results via Form 8-K filings, which summarize revenue from collaborations, research and development expenses, general and administrative expenses, and cash, cash equivalents and marketable securities.

Regulatory and clinical reporting

C4 Therapeutics provides frequent updates on its clinical programs and corporate developments through press releases and SEC filings. These include:

• Quarterly financial results and recent business highlights filed on Form 8-K.
• Regulation FD disclosures for clinical data presentations, such as Phase 1 cemsidomide results presented at the International Myeloma Society Annual Meeting.
• 8-K filings describing material agreements, including the clinical trial collaboration and supply agreement with Pfizer for elranatamab in combination with cemsidomide and dexamethasone in multiple myeloma.
• Corporate governance updates, such as annual meeting voting results and amendments to the certificate of incorporation.

Position within targeted protein degradation

According to its public statements, C4 Therapeutics’ vision is to become a fully integrated biopharmaceutical company that leverages targeted protein degradation across drug discovery, clinical development and commercialization. The company emphasizes the potential for degrader medicines to address diseases driven by proteins that are difficult to inhibit with traditional small molecules, and to provide therapeutic options in oncology and beyond. Its focus on orally bioavailable, brain-penetrant degraders, collaborations with established pharmaceutical partners, and a pipeline that includes both oncology and non-oncology targets are central elements of its stated strategy.